ABP vs MGNX

For growth investors, Abpro Corporation (ABP) is the stronger pick with 50.

0% revenue growth year-over-year, versus 0. 8% for MacroGenics, Inc. (MGNX). Analysts rate MacroGenics, Inc. (MGNX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, MacroGenics, Inc.

(MGNX) delivered a total return of -90. 8%, compared to -99. 7% for Abpro Corporation (ABP). Over 10 years, the gap is even starker: MGNX returned -84. 4% versus ABP's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MacroGenics, Inc.

(MGNX) is the lower-risk stock at 1. 93β versus Abpro Corporation's 2. 59β — meaning ABP is approximately 34% more volatile than MGNX relative to the S&P 500.

By revenue growth (latest reported year), Abpro Corporation (ABP) is pulling ahead at 50.

0% versus 0. 8% for MacroGenics, Inc. (MGNX). On earnings-per-share growth, the picture is similar: Abpro Corporation grew EPS 38. 4% year-over-year, compared to -10. 3% for MacroGenics, Inc.. Over a 3-year CAGR, MGNX leads at -0. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MacroGenics, Inc.

(MGNX) is the more profitable company, earning -49. 9% net margin versus -39. 5% for Abpro Corporation — meaning it keeps -49. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MGNX leads at -48. 7% versus -54. 2% for ABP. At the gross margin level — before operating expenses — ABP leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, MacroGenics, Inc.

(MGNX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Abpro Corporation (ABP) carries a higher beta of 2. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGNX: -84. 4%, ABP: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ABP is a small-cap high-growth stock; MGNX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.